Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 2,195 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $18.03, for a total transaction of $39,575.85. Following the sale, the director directly owned 337,059 shares in the company, valued at $6,077,173.77. This trade represents a 0.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Maplight Therapeutics Stock Down 1.2%

NASDAQ MPLT opened at $17.42 on Friday. The firm has a market capitalization of $790.40 million and a PE ratio of -0.47. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $21.55. The business’s 50 day simple moving average is $17.74.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics in the 4th quarter worth about $70,000. New York State Common Retirement Fund purchased a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $172,000. Finally, Walleye Capital LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $205,000.

Analysts Set New Price Targets

A number of analysts have commented on MPLT shares. Weiss Ratings assumed coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price on the stock. Stifel Nicolaus began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $28.00 price target for the company. Leerink Partners assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Zacks Research raised Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.